Iatrogenic Thoracic Complications Induced by Drugs

  • Steven E. Seltzer
  • Jeffrey D. Goldstein
  • Peter G. Herman
Part of the Radiology of Iatrogenic Disorders book series (IATROGENIC)


Drug-induced diseases account for 3% to 4% of admissions to a medical service (1), and between 5% and 15% of hospitalized patients suffer adverse drug reactions. This takes into account only those events that are associated with prolonged hospital stay, permanent impairment, or death. Three percent of all hospital deaths may be drug-related. It has been estimated that the financial cost of drug-related complications is $3 billion annually (2). Since many iatrogenic complications induced by drugs are associated with abnormal chest radiographs, the radiologist plays an early and important role in diagnosis.


Pulmonary Edema Pulmonary Toxicity Interstitial Pneumonitis Diffuse Alveolar Damage Acute Pulmonary Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Editorial: Disease drugs cause. N Engl J Med 279: 1286–1287, 1968.CrossRefGoogle Scholar
  2. 2.
    De Swarte RD: Drug alergy. In Patterson R (ed): Allergic Diseases, Diagnosis and Management. Philadelphia: JB Lippincott, 1972, pp 393–493.Google Scholar
  3. 3.
    Rosenow EC: The spectrum of drug-induced pulmonary disease. Ann Intern Med 77: 977–991, 1972.PubMedGoogle Scholar
  4. 4.
    Parker CW. Drug allergy. N Engl J Med 292:511–514, 732–736, 957–960, 1975.PubMedCrossRefGoogle Scholar
  5. 5.
    Lakin JD: Hypersensitivity reactions. In Patterson R (ed): Allergic Diseases, Diagnosis and Management. Philadelphia: JB Lippincott, 1972, pp 1–30.Google Scholar
  6. 6.
    Ochsner SF, Hatch HB, Leonard GL: Hypersensitivity and the lung. AJR 107: 390–399, 1969.Google Scholar
  7. 7.
    Ansell G: Radiological manifestations of drug-induced disease. Clin Radiol 20: 133–148, 1969.PubMedCrossRefGoogle Scholar
  8. 8.
    Brettner A, Heitzman ER, Woodin WG: Pulmonary complications of drug therapy. Radiology 96: 31–38, 1970.PubMedGoogle Scholar
  9. 9.
    Heitzman ER: The Lung: Radiologie-Pathologie Correlation. St Louis: CV Mosby, 1973, pp 219– 231.Google Scholar
  10. 10.
    Davies PDB: Drug induced lung disease. Br J Dis Chest 63: 57–70, 1969.CrossRefGoogle Scholar
  11. 11.
    De Weck AL: Drug reactions. In Samter M (ed): Immunological Diseases. Boston: Little Brown, 1971, pp 415–430.Google Scholar
  12. 12.
    Simon G: Type I immunologic reactions in the lung. Semin Roentgenol 10: 21–31, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Freedman PJ: Idiopathic and auto-immune type Ill-like reactions: interstitial fibrosis, vasculitis and granulomatosis. Semin Roentgenol 10: 43–52, 1975.CrossRefGoogle Scholar
  14. 14.
    Samter M, Beers RF: Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 68: 975–983, 1968.PubMedGoogle Scholar
  15. 15.
    Shand DG: Propranolol, N Engl J Med 283: 280, 1975.CrossRefGoogle Scholar
  16. 16.
    Koelle GB: Anticholinesterase agents and parasympathomimetic agents. In Goodman LS, Gilman A (eds): The Pharmacological Basic of Therapeutics. New York: Macmillan, 1975, pp 454–470.Google Scholar
  17. 17.
    Szczekli A, Gryglewski RJ: Prostaglandins and aspirin-sensitive asthma. Am Rev Respir Dis 118: 799–800, 1978.Google Scholar
  18. 18.
    Nash G, Blennerhassett JB, Pontoppidan H, et al: Pulmonary lesions associated with oxygen therapy and artificial ventilation. N Engl J Med 276: 368–374, 1967.PubMedCrossRefGoogle Scholar
  19. 19.
    Senior RM, Wessler S, Avioli LV: Pulmonary oxy-gen toxicity. JAMA 217: 1373–1377, 1971.CrossRefGoogle Scholar
  20. 20.
    Crapo JD, Peters-Golden M, Marsh-Salin J, Shelburne JS: Pathologic changes in the lungs of oxygen-adapted rats—a morphometric analysis. Lab Invest 39: 640, 1978.PubMedGoogle Scholar
  21. 21.
    Stahlman MT: Clinical description of bronchopul-monary dysplasia. J Pediatr 95: 829, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Reid L: Bronchopulmonary dysplasia-pathology. J Pediatr 95: 823, 1979.CrossRefGoogle Scholar
  23. 23.
    Edwards DK: Radiographic aspects of broncho-pulmonary dysplasia. J Pediatr 95: 829, 1979.CrossRefGoogle Scholar
  24. 24.
    Kaufman SK, Nash G: Case records of the Massachusetts General Hospital. N Engl J Med 290: 390–396, 1974.CrossRefGoogle Scholar
  25. 25.
    Pascual RS, Mosher MB, Sikand RS, et al: Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 108: 211–217, 1973.PubMedGoogle Scholar
  26. 26.
    Yagoda A, Mukherji B, Young C, et al: Bleomycin, an anti-tumor antibiotic. Ann Intern Med 77: 861–870, 1972.PubMedGoogle Scholar
  27. 27.
    Rudders RA: Bleomysin: pulmonary toxicity. Ann Intern Med 78: 618, 1973.PubMedGoogle Scholar
  28. 28.
    Iacovino JR, Leitner J, Abbas AK, et al: Fatal pulmonary reaction from low doses of bleomycin. JAMA 235: 1253–1255, 1976.PubMedCrossRefGoogle Scholar
  29. 29.
    Samuels ML, Johnson DE, Holoye PY, et al: Large dose bleomycin therapy and pulmonary toxicity. JAMA 235: 1117–1120, 1976.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldiner PL, Carlon GC, Cvitkovic E, et al: Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1: 1664, 1978.PubMedCrossRefGoogle Scholar
  31. 31.
    De Lena M, Guzzon A, Monfardini S, et al: Clinical radiologic and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin. Cancer Treat Rep (Part 1 ) 56: 343–355, 1972.Google Scholar
  32. 32.
    Richman SD, Levenson SM, Bunn PA, et al: 67Ga accumulation in pulmonary lesions associated with bleomycin toxicity. Cancer 36: 1966–1972, 1975.PubMedCrossRefGoogle Scholar
  33. 33.
    Podoll LN, Winkler SS: Busulfan lung. AJR 120: 151 - 156, 1974.Google Scholar
  34. 34.
    Soble AR, Perry H: Fatal radiation pneumonia following subclinical busulfan injury. AJR 128:15-–18, 1977.Google Scholar
  35. 35.
    Patel AR, Shah PC, Rhee HL, Sasson H, Rao KP: Cyclophosphamide therapy and interstitial pulmonary fibrosis. Cancer 38: 1542, 1976.PubMedCrossRefGoogle Scholar
  36. 36.
    Cole SR, Myers TJ, Klatsky AV: Pulmonary disease with chlorambucil therapy. Cancer 41: 455, 1978.PubMedCrossRefGoogle Scholar
  37. 37.
    Taetle R, Dickman PS, Feldman PS: Pulmonary histopathologic changes associated with melphelan therapy. Cancer 42: 1239, 1978.PubMedCrossRefGoogle Scholar
  38. 38.
    Rodin AE, Haggard ME, Travis LB: Lung changes and chemotherapeutic agents in childhood. Am J Dis Child 120: 337 - 340, 1970.PubMedGoogle Scholar
  39. 39.
    Kuplic JB, Higley CS, Niewoehner DE: Pulmonary ossification associated with long term busulfan therapy in chronic myeloid leukemia. Case report. Am Rev Respir Dis 106: 759–769, 1972.PubMedGoogle Scholar
  40. 40.
    Stott H, Stephens R, Fox W, Vimon G, Roy DC: An investigation of the chest radiographs in a controlled trial of busulfan, cyclophosphamide, and a placebo after resection for carcinoma of the lung. Thorax 31: 265–270, 1976.PubMedCrossRefGoogle Scholar
  41. 41.
    Sostman HD, Matthay RA, Putman CE, Smith CJW: Methotrexate induced pneumonitis. Medicine (Baltimore) 55: 371, 1976.CrossRefGoogle Scholar
  42. 42.
    Gutin PH, Green MR, Bleyer WA, Bauer VL, Wiernik PH, Walker MD: Methotrexate pneumonitis induced by intrathecal methotrexate therapy. Cancer 38: 1529, 1976.PubMedCrossRefGoogle Scholar
  43. 43.
    Everts CS, Westcott JL, Bragg DG: Methotrexate therapy and pulmonary disease. Radiology 107: 539–543, 1973.PubMedGoogle Scholar
  44. 44.
    Weiss RB, Muggia FM: Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med 68: 259, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Aronin PA, Mahaley MS Jr, Rudnick SA, Dudka L, Donohue JF, Selker RG, Moore P: Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N Engl J Med 303: 183–188, 1980.PubMedCrossRefGoogle Scholar
  46. 46.
    Farney RJ, Morris AH, Armstrong JD Jr, Hammer S: Diffuse pulmonary disease after therapy with nitrogen mustard, vincristine, procarbazine, and prednisone. Am Rev Respir Dis 115: 135, 1977.PubMedGoogle Scholar
  47. 47.
    Ecker MD, Jay B, Keohane MF: Procarbazine lung. AJR 131: 527–528, 1978.PubMedGoogle Scholar
  48. 48.
    Seltzer SE, Griffin T, D’Orsi C, Tryka F, Herman PG: Pulmonary reaction associated with neo-carzinostatin (NCS) therapy. Cancer Treat Rep 62: 1270–1271, 1978.Google Scholar
  49. 49.
    Willson JKV: Pulmonary toxicity of antineoplastic drugs. Cancer Treat Rep 62: 2003–2008, 1978.PubMedGoogle Scholar
  50. 50.
    Rokseth R, Storstein O: Pulmonary complications during mecamylamine therapy. Acta Med Scand 167: 23, 1960.PubMedCrossRefGoogle Scholar
  51. 51.
    Heard BE: Fibrous healing of old iatrogenic pulmonary edema (hexamethonium lung). J Pathol 83: 159, 1962.CrossRefGoogle Scholar
  52. 52.
    Perry HM Jr, O’Neal RM, Thomas WA: Pulmonary disease following chronic chemical ganglionic blockade. Am J Med 22: 37, 1957.PubMedCrossRefGoogle Scholar
  53. 53.
    Graham JR, Suby HI, LeCompte PR, et al: Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 274: 259–268, 1966.CrossRefGoogle Scholar
  54. 54.
    Hinde W, Posner E, Sweetnam MT, et al: Pleural effusion and fibrosis during treatment with methysergide. Br Med J 1: 605–606, 1970.CrossRefGoogle Scholar
  55. 55.
    Morrison WJ, Wetherill S, Zyroff J: The acute pulmonary edema of heroin intoxication. Radiology 97: 347–351, 1970.PubMedGoogle Scholar
  56. 56.
    Saba GP, James AE, Johnson BA, et al: Pulmonary complications of narcotic abuse. AJR 122: 740–743, 1974.Google Scholar
  57. 57.
    Steinberg AD, Karliner JS: The clinical spectrum of heroin pulmonary edema. Arch Intern Med 122: 122–127, 1968.PubMedCrossRefGoogle Scholar
  58. 58.
    Duberstein JC, Kaufman DM: A clinical study of an epidemic of heroin intoxication and heroin induced pulmonary edema. Am J Med 51: 704–714, 1971.PubMedCrossRefGoogle Scholar
  59. 59.
    Zyroff J, Slovis TL, Nagler J: Pulmonary edema induced by oral methadone. Radiology 112: 567–568, 1974.PubMedGoogle Scholar
  60. 60.
    Wilen SB, Ulreich S, Rabinowitz JG: Roentgeno- graphic manifestations of methadone induced pulmonary edema. Radiology 114: 51–55, 1975.PubMedGoogle Scholar
  61. 61.
    Bogartz J, Miller WC: Pulmonary edema associated with propoxyphene intoxication. JAMA 215: 259–262, 1971.PubMedCrossRefGoogle Scholar
  62. 62.
    Yound DJ: Propoxyphene suicides: report of nine cases. Arch Intern Med 129: 62–66, 1972.CrossRefGoogle Scholar
  63. 63.
    Halpern M, Citron BP: Necrotizing angitis associated with drug abuse. AJR 111: 663–671, 1971.Google Scholar
  64. 64.
    Tomoshefski JF, Hirsch CS: The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 11: 133, 1980.CrossRefGoogle Scholar
  65. 65.
    Szwed J J: Pulmonary angiothrombosis caused by “blue velvet” addiction. Ann Intern Med 73: 771–774, 1970.PubMedGoogle Scholar
  66. 66.
    Douglas FG, Kafilmont KJ, Patt NL: Foreign particle embolism in drug addicts: respiratory pathophysiology. Ann Intern Med 75: 865–872, 1971.PubMedGoogle Scholar
  67. 67.
    Richman S, Harris RD: Acute pulmonary edema associated with Librium abuse. Radiology 103: 57–58, 1972.PubMedGoogle Scholar
  68. 68.
    Bledsoe FH, Seymour EQ: Acute pulmonary edema associated with parathion poisoning. Radiology 103: 53–56, 1972.PubMedGoogle Scholar
  69. 69.
    Steinberg AD: Pulmonary edema following ingestion of hydrochlorothiazide. JAMA 204: 825–827, 1968.PubMedCrossRefGoogle Scholar
  70. 70.
    Broderick TW, Reinke RT, Goldman E: Salicylate-induced pulmonary edema. AJR 127: 865–866, 1976.PubMedGoogle Scholar
  71. 71.
    Marshall A, Moore K: Pulmonary disease after amitriptyline overdosage. Br Med J 1: 716–717, 1973.PubMedCrossRefGoogle Scholar
  72. 72.
    Greganti MA, Flowers WM: Acute pulmonary edema after intravenous administration of contrast media. Radiology 132: 583–585, 1979.PubMedGoogle Scholar
  73. 73.
    Lascari AD, Strano AJ, Johnson WW, Collins JGP: Methotrexate induced sudden fatal pulmonary reaction. Cancer 40: 1393, 1977.PubMedCrossRefGoogle Scholar
  74. 74.
    Haupt JM, Hutchins GM, Moore GW: ARA-C lung: alveolar-capillary leak complicating cytosine arabinoside therapy of leukemia. Lab Invest 42: 26, 1980.Google Scholar
  75. 75.
    Ward HN: Pulmonary infiltrates associated with leukoagglutinin transfusion reactions. Ann Intern Med 73: 689–694, 1970.PubMedGoogle Scholar
  76. 76.
    Wright DG, Robichard KJ, Pizzo PA, Deisseroth AB: Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 304: 1185–1189, 1981.PubMedCrossRefGoogle Scholar
  77. 77.
    Eltringham JR, Fajardo LF, Stewart R: Adriamycin cardiomyopathy: enhanced cardiac damage in rabbits with combined drug and cardiac irradiation. Radiology 115: 471–472, 1975.PubMedGoogle Scholar
  78. 78.
    Mills BA, Roberts RW: Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature. Cancer 43: 2223, 1979.PubMedCrossRefGoogle Scholar
  79. 79.
    Raskin MM, Rajurkar MG, Altman DH. Daunomycin cardiac toxicity. AJR 118: 68–71, 1973.Google Scholar
  80. 80.
    Calabresi P, Parks RE: Alkylating agents, antimetabolites, hormones, and other antiproliferative agents. In Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York: Macmillan, 1975, p 1291.Google Scholar
  81. 81.
    Donlan CJ, Scutero JV: Transient eosinophilic pneumonia secondary to use of a vaginal cream. Chest 67: 232, 1975.PubMedCrossRefGoogle Scholar
  82. 82.
    Kilburn KH: Pulmonary disease induced by drugs. In Fishman AP (ed): Pulmonary Diseases and Disorders. New York: McGraw-Hill, 1979, p 717.Google Scholar
  83. 83.
    Ellis RV, McKenzie CA: Allergic pneumonia. J Lab Clin Med 26: 1427–1432, 1941.Google Scholar
  84. 84.
    Fiegenberg HW, Weiss H, Kushman H: Migratory pneumonia with eosinophilia associated with sulphonamide administration. Arch Intern Med 120: 85–92, 1967.PubMedCrossRefGoogle Scholar
  85. 85.
    Klinghoffer JF: Loeffler’s syndrome following use of vaginal cream. Ann Intern Med 40: 343–350, 1954.PubMedGoogle Scholar
  86. 86.
    Riechlin S, Loveless MH, Kane EG: Loeffler’s syndrome following penicillin therapy. Ann Intern Med 38: 113–120, 1953.Google Scholar
  87. 87.
    Simpson DG, Walker JA: Hypersensitivity to paraaminosalicylic acid. Am J Med 29: 297–306, 1960.CrossRefGoogle Scholar
  88. 88.
    Hailey FJ, Glascock HW, Hewitt WF: Pleuro-pneumonic reactions to nitrofurantoin. N Engl J Med 281: 1087–1090, 1969.PubMedCrossRefGoogle Scholar
  89. 89.
    Ngan BH, Millard RJ, Lant AE, et al: Nitrofurantoin lung. Br J Radiol 44: 21–23, 1971.PubMedCrossRefGoogle Scholar
  90. 90.
    Risk AA: Brief recording: anaphylactoid reaction to nitrofurantoin. N Engl J Med 245: 1054, 1957.Google Scholar
  91. 91.
    Murray MH, Kronenberg P: Pulmonary reaction simulating cardiac pulmonary edema caused by nitrofurantoin. N Engl J Med 273: 1185 - 1187, 1965.PubMedCrossRefGoogle Scholar
  92. 92.
    Israel HL, Diamont P: Recurrent pulmonary infil-tration and pleural effusion due to nitrofurantoin sensitivity. N Engl J Med 266: 1024–1026, 1962.CrossRefGoogle Scholar
  93. 93.
    Bayer WL, Dawson RB, Kotin E: Allergic tracheo-bronchitis due to nitrofurantoin sensitivity. Dis Chest 48: 429–430, 1965.PubMedCrossRefGoogle Scholar
  94. 94.
    Wilson ES, McCarty RJ: Nitrofurantoin pneumonia. AJR 103: 540–542, 1968.Google Scholar
  95. 95.
    Glueck MA, Janower ML: Nitrofurantoin lung disease. AJR 107: 818–822, 1969.Google Scholar
  96. 96.
    Allen RW, Holt AH, Brown MG: Acute pulmonary sensitivity to nitrofurantoin. AJR 104:784–785, 1968.Google Scholar
  97. 97.
    Krush ED, Mostyn EM, Persky L: Nitrofurantoin pulmonary complications. J Urol 113: 392–395, 1975.Google Scholar
  98. 98.
    Carrington CB, Addington WW, Goff AM, Madoff IM, Marks A, Schwaber JR, Gaensler EA: Chronic eosinophilic pneumonia. N Engl J Med 280: 787, 1969.PubMedCrossRefGoogle Scholar
  99. 99.
    Rosenow EC, De Remee RA, Dinen DW: Chronic nitrofurantoin pulmonary reaction. N Engl J Med 279: 1258–1262, 1968.PubMedCrossRefGoogle Scholar
  100. 100.
    Cortez LM, Pankey GA: Acute pulmonary sensitivity to furazolidone. Am Rev Respir Dis 105: 823–826, 1972.PubMedGoogle Scholar
  101. 101.
    Bone RC, Wolfe J, Sobonya RE, Kerby GR, Strechschulte D, Ruth WE, Welch M: Desquamative interstitial pneumonitis following chronic nitrofurantoin therapy. Chest 69: 296–297, 1976.PubMedGoogle Scholar
  102. 102.
    Felton WL II: The reaction of pulmonary tissue to Lipiodol. J Thorac Surg 25: 530, 1953.PubMedGoogle Scholar
  103. 103.
    Smith TR, Frater R, Spataro J: Delayed granuloma following bronchography. Chest 64: 122, 1973.PubMedCrossRefGoogle Scholar
  104. 104.
    Fraimow W, Wallace S, Lewis P, Greening RR, Cathcart RT: Changes in pulmonary function due to lymphangiography. Radiology 85: 231, 1965.PubMedGoogle Scholar
  105. 105.
    Weill H, Ferrans VJ, Gay RM, et al: Early lipoid pneumonia: roentgenologic, anatomic, and physio-logic characteristics. Am J Med 36: 370–376, 1964.PubMedCrossRefGoogle Scholar
  106. 106.
    Pepys J, Jenkins PA, Lackman PJ, et al: An iatrogenic auto antibody immunological response to pituitary snuff in patients with diabetes insipidus. Clin Exp Immunol 1: 377–389, 1966.PubMedGoogle Scholar
  107. 107.
    Harper LO, Burreil RG, Lapp NL, et al: Allergic alveolitis due to pituitary snuff. Ann Intern Med 73: 581–584, 1970.PubMedGoogle Scholar
  108. 108.
    McCoombs RP, Patterson JF, MacMahon HE: Syndromes associated with allergic vasculitis. N Engl J Med 255: 251–261, 1956.CrossRefGoogle Scholar
  109. 109.
    Symmers WS: The occurrence of angiitis and of other generalized diseases of connective tissues as consequence of administration of drugs. Proc R Soc Med 55: 20–28, 1962.Google Scholar
  110. 110.
    Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio J J: Drug related vasculitis, clinicopatho-logic correlations in 30 patients. Hum Pathol 10: 313–325, 1979.PubMedCrossRefGoogle Scholar
  111. 111.
    Churg J, Strauss L: Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 27: 277, 1951.PubMedGoogle Scholar
  112. 112.
    Gurtner HP: Pulmonary hypertension produced by the ingestion of substances. Bull Physio-Pathol Resp 5: 435, 1969.Google Scholar
  113. 113.
    Auerbach RC, Snyder NE, Bragg DG: The chest roentgenographic manifestations of pronestyl-in- duced lupus erythematosus. Radiology 109: 287–290, 1973.PubMedGoogle Scholar
  114. 114.
    Alarcon-Segovia D: Drug-induced lupus syndrome. Mayo Clin Proc 44: 664–681, 1969.PubMedGoogle Scholar
  115. 115.
    Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298: 1157, 1978.PubMedCrossRefGoogle Scholar
  116. 116.
    Brodelius A, Lorinc P, Nylander G: Localization of acute deep venous thrombosis in women taking oral contraceptives. Radiology 101: 297–300, 1971.PubMedGoogle Scholar
  117. 117.
    Sparberg M: Diagnostically confusing complications of diphenylhydantoin therapy. Ann Intern Med 59: 914–930, 1963.PubMedGoogle Scholar
  118. 118.
    Saltzstein SL, Ackerman LV: Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically the malignant lymphomas. Cancer 12: 164–182, 1959.PubMedCrossRefGoogle Scholar
  119. 119.
    Dorfman RF, Warnke R: Lymphadenopathy stimulating the malignant lymphomas. Hum Pathol 5: 519, 1974.PubMedCrossRefGoogle Scholar
  120. 120.
    Heitzman ER: Lymphadenopathy related to anti-convulsant therapy. Radiology 89: 311–312, 1967.Google Scholar
  121. 121.
    Bayer AS, Targan SR, Pitchon HE, et al: Dilantin toxicity: miliary pulmonary infiltrates and hypoxemia. Ann Intern Med 85: 475–476, 1976.PubMedGoogle Scholar
  122. 122.
    Hazlett DR, Ward GW, Madison DS. Pulmonary function loss in diphenylhydantoin therapy. Chest 66: 660–664, 1974.PubMedCrossRefGoogle Scholar
  123. 123.
    Moore MT: Pulmonary changes in hydantoin therapy. JAMA 171: 1328–1333, 1959.CrossRefGoogle Scholar
  124. 124.
    Low NL, Yahr MD: The lack of pulmonary fibrosis in patients receiving diphenylhydantoin. JAMA 174: 1201–1202, 1960.PubMedCrossRefGoogle Scholar
  125. 125.
    Livingston S, Whitehouse D, Panci LL: Study of the effects of diphenylhydantoin sodium on the lungs. N Engl J Med 264: 648–651, 1961.PubMedCrossRefGoogle Scholar
  126. 126.
    Teates CD: Steroid-induced mediastinal lipomatosis. Radiology 96: 501–502, 1970.PubMedGoogle Scholar
  127. 127.
    Koerner HJ, Sun DI: Mediastinal lipomatosis secondary to steroid therapy. AJR 98: 461–464, 1966.Google Scholar
  128. 128.
    Bodman SF, Condemi JJ: Mediastinal widening in iatrogenic Cushing’s syndrome. Ann Intern Med 67: 399–403, 1967.PubMedGoogle Scholar
  129. 129.
    Petusevsky ML, Faling LF, Rocklin RG, et al: Pleuropericardial reaction to treatment with Dantrolene. JAMA 242: 2772–2774, 1979.PubMedCrossRefGoogle Scholar
  130. 130.
    Morrison DA, Goldman AL: Radiographic patterns of drug-induced lung disease. Radiology 131: 299–304, 1979.PubMedGoogle Scholar
  131. 131.
    Seltzer SE, Herman PG: Drug-induced pulmonary reactions associated with abnormal chest radiograph. J Contin Educ Radiol 1: 25–42, 1979.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1983

Authors and Affiliations

  • Steven E. Seltzer
  • Jeffrey D. Goldstein
  • Peter G. Herman

There are no affiliations available

Personalised recommendations